Literature DB >> 178074

Uterine estrogen receptor binding of catecholestrogens and of estetrol (1,3,5(10)-estratriene-3,15alpha,16alpha,17beta-tetrol).

C Martucci, J Fishman.   

Abstract

The binding affinities for the catecholestrogen metabolites of estradiol and of their methyl ethers for the rat uterine cytosol estrogen receptors were examined. Similarly the binding of the fetal estradiol metabolite, 15alpha-hydroxyestriol (estertrol) was also measured. All of the catecholestrogens showed binding affinities far in excess of their uterotrophic potency. This is different from estriol, the product of the alternative metabolic pathways and suggests that the direction of estradiol metabolism may have an important role in the modulation of estrogenic activity of the female sex hormone.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 178074     DOI: 10.1016/0039-128x(76)90054-4

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  11 in total

Review 1.  Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes.

Authors:  Hyunyoung Jeong
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-06       Impact factor: 4.481

2.  Estradiol-17beta and its cytochrome P450- and catechol-O-methyltransferase-derived metabolites stimulate proliferation in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta.

Authors:  Sheikh O Jobe; Jayanth Ramadoss; Jill M Koch; Yizhou Jiang; Jing Zheng; Ronald R Magness
Journal:  Hypertension       Date:  2010-03-08       Impact factor: 10.190

Review 3.  Importance of catecholestrogens in the regulation of the ovarian cycle.

Authors:  P Ball; G Emons; R Knuppen
Journal:  Arch Gynecol       Date:  1982

4.  3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound.

Authors:  G Kranzfelder; R W Hartmann; E von Angerer; H Schönenberger; A E Bogden
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

5.  Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.

Authors:  Jehana James; Daryl J Murry; Anthony M Treston; Anna Maria Storniolo; George W Sledge; Carolyn Sidor; Kathy D Miller
Journal:  Invest New Drugs       Date:  2006-09-13       Impact factor: 3.850

6.  Non-genomic mechanism of 17 beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle.

Authors:  T Kitazawa; E Hamada; K Kitazawa; A K Gaznabi
Journal:  J Physiol       Date:  1997-03-01       Impact factor: 5.182

7.  A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Authors:  Michael R Harrison; Noah M Hahn; Roberto Pili; William K Oh; Hans Hammers; Christopher Sweeney; Kyungmann Kim; Scott Perlman; Jamie Arnott; Carolyn Sidor; George Wilding; Glenn Liu
Journal:  Invest New Drugs       Date:  2010-05-25       Impact factor: 3.850

8.  Synthesis and evaluation of catechol analogs of diethylstilbestrol on a hormone-dependent human mammary carcinoma implanted in nude mice.

Authors:  M R Schneider; H Schönenberger; R T Michel; H P Fortmeyer
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

9.  Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.

Authors:  Yuan Ji; Janet Olson; Jianping Zhang; Michelle Hildebrandt; Liewei Wang; James Ingle; Zachary Fredericksen; Thomas Sellers; William Miller; J Michael Dixon; Hiltrud Brauch; Michel Eichelbaum; Christina Justenhoven; Ute Hamann; Yon Ko; Thomas Brüning; Jenny Chang-Claude; Shan Wang-Gohrke; Daniel Schaid; Richard Weinshilboum
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Growth-promoting effect of oestriol in a lymphoma lacking oestrogen receptors.

Authors:  R Kawatsu; T Ezaki; M Kotani; M Akagi
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.